What does DrugPatentWatch list for nivolumab (Opdivo)?
DrugPatentWatch tracks patents and exclusivity claims tied to nivolumab (marketed as Opdivo). To see the exact patent-by-patent details (including relevant jurisdictions and estimated timelines), you can search nivolumab directly on DrugPatentWatch: https://www.drugpatentwatch.com/patent/Opdivo
What patents or exclusivity should I look for on the nivolumab page?
On the DrugPatentWatch listing, the most useful items to review typically include:
- Patent numbers covering the product and key formulations/methods.
- Patent status (for example, whether patents appear active, challenged, or expired).
- Any links to litigation or challenges that could affect when generic or biosimilar competition may enter.
These items determine when other companies can potentially launch competing versions, even if marketing exclusivity is still in effect. [1]
Is nivolumab a biosimilar target, and when might competition start?
Nivolumab is a biologic, so the relevant future competition is usually biosimilars rather than small-molecule generics. DrugPatentWatch is designed to help estimate when biosimilar entry could become possible based on the listed patents and exclusivity windows. Check the nivolumab/Opdivo patent page for the dates and which patents are likely driving the exclusivity period. [1]
Can I use DrugPatentWatch to find challenges (e.g., patent disputes)?
Yes. DrugPatentWatch commonly surfaces information that can help you find whether companies have moved against specific patents (for example, via legal challenges), which can influence the effective launch timing of biosimilar products. Use the nivolumab/Opdivo page to follow the specific patent records and any related notes. [1]
Which company manufactures nivolumab (Opdivo)?
The DrugPatentWatch page for Opdivo is the fastest way to confirm the listed brand/manufacturer context tied to the patents it tracks. Use the link above to verify the responsible entity shown on that listing. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/Opdivo